At present, PD-1/PD-L1 inhibitors have been approved by the FDA for numerous types of cancer, including melanoma, NSCLC, head and neck squamous cell cancer, urothelial cancer, liver cancer, Hodgkin’s lymphoma, renal cell cancer (RCC), gastric cancer, and colorectal cancer [5]. The gene discussed is CD274; the disease is renal cell adenocarcinoma.